Koyfin Home > Directory > Health Care > Akebia Therapeutics > Repurchase of Common Stock

Akebia Therapeutics Repurchase of Common Stock Chart (AKBA)

Akebia Therapeutics annual/quarterly Repurchase of Common Stock from 2014 to 2019.
  • Akebia Therapeutics Repurchase of Common Stock for the quarter ending December 12, 2019 was $0m a 0.00% increase of 0m year over year
  • Akebia Therapeutics Repurchase of Common Stock for the last 12 months ending June 06, 2020 was $0m a 0.00% increase of 0m year over year
  • Akebia Therapeutics Annual Repurchase of Common Stock for 2019 was $0m a 61.97% decrease of 0m from 2018
  • Akebia Therapeutics Annual Repurchase of Common Stock for 2014 was $0m
Other Cash Flow Metrics:
  • Akebia Therapeutics Cash Flow from Operations for the quarter ending December 12, 2018 was $-74m a 72.41% decrease of -53m year over year
  • Akebia Therapeutics Levered Free Cash Flow (FCF) for the quarter ending December 12, 2018 was $-92m a 89.67% decrease of -82m year over year
  • Akebia Therapeutics Total Revenue for the quarter ending December 12, 2018 was $60m a 23.26% increase of 14m year over year
View Chart On Koyfin

Quarterly AKBA Repurchase of Common Stock Data

12/2019$0m
09/2019$0m
06/2019$0m
06/2016$0m
12/2014$0m
09/2014$0m
06/2014$0m

Annual AKBA Repurchase of Common Stock Data

2019$0m
2014$0m